Search

Ergoloid mesylate

[L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA. … Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine.

Avibactam

This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract … Avibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz).

Daclizumab

in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not hight immunized, for commercial reasons … The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody.

Enzalutamide

[L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. … [A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007.

Nabiximols

In Canada, Sativex® has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded … This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes.

Carteolol

A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.

Tarenflurbil

Tarenflurbil is an investigational drug that was studied in patients with mild Alzheimer's disease. … It is a selective amyloid lowering agent (SALA) that reduces levels of the toxic peptide amyloid beta 42 (Aβ42) in cultured human cells and in animal models.

Sinapultide

[L2504] Windtree is currently developing aerosolized KL4 surfactant to treat RDS in premature infants, and thereafter, to potentially address a range of indications in neonatal, pediatric and adult … [L2502] Windtree Therapeutics plans a phase III trial for Respiratory distress syndrome in 2018.

Rose bengal I-131

Bethanechol

Bethanechol is a synthetic ester that was initially synthesized in 1935. … An advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539]